7-benzyl-8-chloro-1,3-dimethyl-1,3,7-trihydropurine-2,6-dione | 109286-40-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 7-benzyl-8-chloro-1,3-dimethyl-1,3,7-trihydropurine-2,6-dione
• 英文别名: 7-benzyl-8-chloro-1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione；7-benzyl-8-chloro-1,3-dimethyl-3,7-dihydro-purine-2,6-dione；7-benzyl-8-chloro-1,3-dimethyl-3,7-dihydropurine-2,6-dione；7-benzyl-8-chloro-1,3-dimethyl-1H-purine-2,6(3H,7H)-dione；8-chloro-7-benzyltheophylline；1,3-dimethyl-7-benzyl-8-chloro-xanthine；7-benzyl-8-chloro-1,3-dimethylpurine-2,6-dione
• CAS: 109286-40-0
• 化学式: C₁₄H₁₃ClN₄O₂
• mdl: MFCD01419743
• 分子量: 304.736
• InChiKey: MFFGCBDQVBOJBG-UHFFFAOYSA-N

物化性质

• 熔点：
  153 °C(Solv: ethanol (64-17-5))
• 沸点：
  527.8±60.0 °C(Predicted)
• 密度：
  1.43±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.214
• 拓扑面积：
  58.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  7-benzyl-8-chloro-1,3-dimethyl-1,3,7-trihydropurine-2,6-dione 在 一水合肼 作用下， 以73%的产率得到7-benzyl-8-hydrazino-1,3-dimethyl-3,7-dihydropurine-2,6-dione
  参考文献：
  名称：

  Design and synthesis of EGFR dimerization inhibitors and evaluation of their potential in the treatment of psoriasis

  摘要：

  Hit compounds from in silico screening for inhibitors of the EGFR dimerization process were evaluated for their anti-proliferative (CCD-1106 keratinocytes) and anti-oxidant (TBA assay) activity and their effect on EGFR dimerization (BS3 chemical crosslinking assay). 7-Benzyl-8-{N'-[1-( 3-ethoxy-4-hydroxyphenyl)meth-(Z)-ylidene]hydrazino}-1,3-dimethylxanthine 2a (127 mu M) leads to 37% inhibition of p-EGFR dimerization in the CCD-1106 cell line and also inhibits phosphorylation of proteins in the MAPK/ERK pathway, ERK 1/2 and p-38. Based on this initial data, 2a was selected for further study and was evaluated for its anti-proliferative activity in a range of keratinocyte (CCD-1106, HaCaT and NHEK) and monocyte (ThP1 and U937) cell lines. Xanthine 2a is pro-apoptotic in HaCaT keratinocytes, as shown by electron microscopy, caspase 3/7, and annexin V-FITC/PI flow cytometric assays. It is significantly less cytotoxic than the established antipsoriatic agent dithranol 14, as determined by MTT and LDH release assays, and thus has potential as a lead compound for the treatment of psoriasis. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2012.07.048
• 作为产物：
  描述：

  1,3-二甲基-8-硝基-1H-嘌呤2,6(3H,9H)-二酮 在 盐酸 、 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 7-benzyl-8-chloro-1,3-dimethyl-1,3,7-trihydropurine-2,6-dione
  参考文献：
  名称：

  Mosselhi, Mosselhi A. N.; Abbass, Ikhlass M., Bulletin of the Polish Academy of Sciences: Chemistry, 1993, vol. 41, # 3, p. 179 - 186

  摘要：

  DOI：

文献信息

• [EN] SMALL MOLECULE ALDEHYDE DEHYDROGENASE INHIBITORS AND METHODS OF USE THEREOF<br/>[FR] PETITES MOLÉCULES INHIBITEURS DES ALDÉHYDE-DÉSHYDROGÉNASES ET LEURS MÉTHODES D'UTILISATION
  申请人：US HEALTH

  公开号：WO2016086008A1

  公开（公告）日：2016-06-02

  Described herein are compounds, salts and solvates of the formula (I). Certain compounds of formula (I) are potent and selective inhibitors of aldehyde dehydrogenases (ALDH), a family of enzymes that play a critical role in detoxification of various cytotoxic xenogenic and biogenic aldehydes. As such, compounds of formula (I) are useful for treating disorders in which ALDH inhibition is needed, including cancer, inflammatory disorders, and obesity. The disclosure also includes compositions, and methods for inhibiting aldehyde dehydrogenases (ALDH).

  本发明涉及公式(I)的化合物、盐和溶剂化物。公式(I)的某些化合物是醛脱氢酶(ALDH)的强效和选择性抑制剂，ALDH是一类在解毒各种细胞毒性的异生物质和生物源性醛方面发挥关键作用的酶。因此，公式(I)的化合物可用于治疗需要ALDH抑制的疾病，包括癌症、炎症性疾病和肥胖。本发明还包括用于抑制醛脱氢酶(ALDH)的组合物和方法。
• Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
  申请人：——

  公开号：US20020198205A1

  公开（公告）日：2002-12-26

  The present invention relates to substituted xanthines of general formula 1 wherein R 1 to R 4 are defined as in claim 1, the tautomers and the stereoisomers thereof, mixtures thereof, the prodrugs and the salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).

  本发明涉及一般式1的取代黄嘌呤，其中R1至R4如权利要求1中定义，其互变异构体和立体异构体，其混合物，其前药和其盐，具有有价值的药理特性，特别是对酶二肽基肽酶-IV（DPP-IV）活性的抑制作用。
• [EN] XANTHINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS<br/>[FR] DERIVES DE XANTHINE SERVANT D'ANTAGONISTES DU RECEPTEUR DE L'ADENOSINE A2B
  申请人：CV THERAPEUTICS INC

  公开号：WO2004106337A1

  公开（公告）日：2004-12-09

  Disclosed are compounds that are A2B adenosine receptor antagonists, useful for treating various disease states, including asthma and diarrhea.

  揭示了一种A2B腺苷受体拮抗剂化合物，可用于治疗包括哮喘和腹泻在内的各种疾病状态。
• A2B adenosine receptor antagonists
  申请人：Kalla Rao

  公开号：US20050101778A1

  公开（公告）日：2005-05-12

  Disclosed are novel A 2B adenosine receptor antagonists having the structure of Formula I or Formula II: The compounds are particularly useful for treating asthma, inflammatory gastrointestinal tract disorders, cardiovascular diseases, neurological disorders, and diseases related to undesirable angiogenesis.

  揭示了具有Formula I或Formula II结构的新型A2B腺苷受体拮抗剂：这些化合物特别适用于治疗哮喘、炎症性胃肠道疾病、心血管疾病、神经系统疾病以及与不良血管生成相关的疾病。
• A2B Adenosine receptor antagonists
  申请人：Kalla Rao

  公开号：US20050261316A1

  公开（公告）日：2005-11-24

  Disclosed are novel compounds that are A 2B adenosine receptor antagonists, useful for treating various disease states, including asthma and diarrhea.

  揭示了一种新颖的化合物，它们是A2B腺苷受体拮抗剂，可用于治疗包括哮喘和腹泻在内的各种疾病状态。